- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Immunomedics wins $7.5 million financing
In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.Morris
In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.
Morris Plains, NJ-based Immunomedics plans to use the proceeds of the stock sale to redeem remaining shares of its outstanding preferred stock. In November, the company made an agreement with HFTP Investment to buy 445 of HFTPs preferred shares in the company. The holder of the firms remaining 150 preferred shares, which Immunomedics declined to name, has also agreed to sell those shares to the firm.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
